Monoclonal antibodies (MAb) directed against bacterial lipopolysaccharide (LPS) and tumor necrosis factor-alpha (TNF) provide partial protection in experimental models of septic shock. To determine if additional benefit accrues from a combination of anti-TNF and anti-LPS MAb in the treatment of septic shock, a neutropenic rat model was developed to study active infection with Pseudomonas aeruginosa 12.4A. Animals were treated intravenously with an irrelevant MAb (group 1); anti-TNF MAb (group 2); MAb directed against P. aeruginosa 12.4.4 LPS (group 3); or a combination of anti-TNF and anti-LPS MAb (group 4). None of the control animals in group 1 survived the 7-d period of neutropenia (0/16). In contrast, the survival rate was 44% in group 2 (P < 0.02); 37% in group 3 (P < 0.05); and 75% in group 4 (P < 0.0002). The combination of monoclonal antibodies provided greater protection than either MAb given alone (P < 0.05). Serum TNF levels during infection were significantly greater in groups 1 and 3 (20.1±3.3 U. mean±SE) than in groups 2 and 4 (0.9±0.8 U, P < 0.0001). These results indicate that a combination of monoclonal antibodies to LPS and TNF have additive benefit in experimental Pseudomonas aeruginosa sepsis. This immunotherapeutic approach may be of potential utility in the management ofserious, gram-negative bacterial infection in neutropenic patients. (J.
Introduction
Septic shock continues to be associated with an unacceptably high mortality rate despite the availability of a wide variety of potent antimicrobial agents (1, 2) . Consequently, other forms of treatment, such as immunotherapy, have been studied to supplement conventional therapy with antibiotics and supportive care. Both standard immune globulin and immunoglobulin that is hyperimmune to specific bacterial surface determinants have been shown to mediate opsonophagocytosis of bacteria in vitro and to offer protection in animal models of infection Receivedforpublication 13 March 1990 and in revisedform 5 May 1991. (3) . These products are currently undergoing clinical evaluation (4) .
In addition, other strategies for the immunotherapy of septic shock have been suggested. The hemodynamic and pathologic consequences of septic shock caused by gram-negative bacilli are principally triggered by bacterial endotoxin or lipopolysaccharide (LPS) . Circulating levels of endotoxin accompany active gram-negative bacteremia and may be transiently elevated after the initiation of antimicrobial therapy, presumably from the lysis of bacteria (5) . Circulating endotoxin initiates a cascade of potentially harmful biologic effects. A useful strategy to prevent the deleterious effects of endotoxin might include the provision ofpassive immunity against bacterial endotoxin itself (6) . Therapy with polyclonal and monoclonal antibody directed against widely shared epitopes in the core glycolipid of LPS has been shown to be partially protective in a number of experimental and clinical studies of septic shock (7, 8) .
Recent evidence indicates that the proinflammatory cytokine tumor necrosis factor-alpha (TNF) is an important mediator of the hemodynamic and pathophysiologic effects of endotoxin (9, 10) . Polyclonal and monoclonal antibodies directed against TNF protect animals from otherwise lethal doses of endotoxin (11) (12) (13) (14) and massive intravenous doses of viable Escherichia coli (15) . Anti-TNF monoclonal antibodies have recently been administered to septic patients in a phase I human trial (16).
Utilizing a recently developed neutropenic rat model ofactive Pseudomonas sepsis, we have demonstrated that antimicrobial agents combined with a monoclonal antibody against the O-side chain of LPS (17) or combined with a monoclonal antibody against TNF (18) provide protection from lethal infection. Because each of these monoclonal antibodies act at a different phase in the development of the septic state, we sought to determine if a combination both monoclonal antibodies would be superior to either monoclonal antibody alone in the protection of neutropenic animals during Pseudomonas sepsis.
followed by a second dose of 50 mg/kg i.p. 72 h later. An oral challenge with a virulent, human isolate ofPseudomonas aeruginosa (P. aeruginosa 12.4.4, provided by Dr. A. McManus, San Antonio, TX) was given by orogastric feeding tube time 0, 48, and 96 h after the administration ofthe first dose ofcyclophosphamide. The challenge strain was given at a dose of -106 organisms in 1 ml ofPBS. All manipulations of the animals were conducted under light CO2 anesthesia to minimize trauma to the animals. Quantitative blood cultures, complete blood counts, and other serum determinations were obtained 24 h before the first dose ofcyclophosphamide and at 72 and 120 h after cyclophosphamide. Blood cultures were obtained by plating 100 ul ofblood directly on MacConkey's media (BBL Microbiology Systems, Cockeysville, MD). Plates were then incubated at 370C for 48 h and examined for visible growth ofbacterial colonies. Animals were examined daily, and necropsy examinations were performed within 24 h after death. All surviving animals were sacrificed at the end of the experiment and underwent necropsy examination as well.
Monoclonal antibody treatment. A hamster-derived anti-murine TNF-alpha monoclonal antibody (TN3 19.12) was provided by R. Schreiber, Washington University, St. Louis, MO. This IgG MAb neutralizes natural rat tumor necrosis factor-alpha in an L929 cytotoxicity assay at a level of 19 ng/U TNF (19) . The anti-TNF MAb was given intravenously via tail vein at a dose of 20 mg/kg at time 0 and 120 h.
A serotype-specific MAb directed against Pseudomonas aeruginosa 12.4.4 (designated MAb 11.14.1) was derived from mouse ascitic fluid as previously described (17, 20) . This MAb is of the IgG, isotype and was given intravenously at adose of2.5 mg/kg at time 0 and 120 h. The antibody has previously been shown to possess serotype-specific opsonophagocytic activity and to protect rodents from lethal challenge with P. aeruginosa 12.4.4 (20) . To determine ifMAb 11.14.1 possessed antiendotoxin activity, SDS-PAGE of P. aeruginosa LPS immunotypes [1] [2] [3] [4] [5] [6] [7] and Western blots were performed as previously described (20) . Limulus lysate reactivity by the turbidometric method (Associates of Cape Cod, Woods Hole, MA) was used to compare endotoxin activity of P. aeruginosa 12.4.4 LPS before and after the addition of MAb 11.14.1.
A control MAb was also utilized in these experiments as an irrelevant MAb. This MAb was designated L2 3D9 and was given at a dose of 20 mg/kg intravenously. The monoclonal antibodies used in these experiments were endotoxin free (< 0.05 gg/mg of protein), as determined by Limulus lysate turbidometric assay. The L2 3D9 MAb was hamster derived and was directed against recombinant murine interleukin 2. It does not react with natural mouse or rat interleukin 2. This monoclonal antibody was prepared in a similar fashion to that ofTN3 19.12, the anti-TNF monoclonal antibody.
Blood determinations and necropsy studies. Serum TNF levels were measured using the L929 fibroblast cytotoxicity assay 24 hours before the first dose ofcyclophosphamide and 120 h later. The serum determinations at 120 h were obtained just before the MAb treatment in each animal. The data are presented in TNF units with one unit indicating the level ofTNF required to produce 50% cytotoxicity ofthe L929 cells. One unit equals -22 pg/ml of TNF in this assay system (21) .
Serum levels of anti-TNF monoclonal antibody levels 4 h after an intravenous administration of 20 mg/kg of TN3 19.12 (n = 4) were determined by a direct ELISA system using a peroxidase-labeled goat anti-hamster IgG antibody (19) . Serum levels ofthe anti-LPS monoclonal antibody 11.14.1 (n = 4) were measured with an ELISA system with outer membrane complex as the antigen as previously described (17) .
At necropsy, all animals had tissue cultures performed of lung, heart, spleen, liver, and cecum. Nonlactose fermenting, oxidase-positive colonies which appeared on MacConkey's agar were further identified by agglutination reactions with a polyvalent Pseudomonas aeruginosa antisera set (Difco, Detroit, MI). The challenge strain of Pseudomonas aeruginosa 12.4.4 belongs to Fisher-Devlin-Gnabasik immunotype 6 (17) .
Histologic sections oflung, cecum, and kidney tissue were obtained from five lethally infected control animals (group 1) as well as five animals which survived the experiment (group 4 Fig. 1) . Animals which received saline alone (n = 16) also had a 100% mortality rate (data not shown). Animals treated with anti-TNF MAb alone (group 2) showed a survival rate of 44% providing a significant survival advantage over group 1 animals (P < 0.02). Animals receiving anti-LPS MAb (group 3) exhibited a 37% survival rate, which was also significantly greater than group 1 animals (P < 0.05). Group 4 animals, which received anti-LPS as well as anti-TNF MAb had a 75% survival rate (12/16). Group 4 animals were protected from lethality at a much greater level than group 1 animals (P < 0.0003) or either MAb given alone (P<0.05) (Fig. 1) .
All animals were found to be severely neutropenic with absolute granulocyte counts of < 100 granulocytes per microliter by 120 h. Blood cultures obtained 24 h before the first dose ofcyclophosphamide revealed no positive blood cultures for P. aeruginosa. Random blood cultures obtained at 72 and 120 h after cyclophosphamide demonstrated no significant differences in the frequency of Pseudomonas bacteremia between each group: group 1,36%; group 2,42%; group 3,36%; group 4, 38% (P = NS). Nonetheless, groups receiving anti-LPS MAb (groups 3 and 4) had a significantly lower quantitative level of bacteremia than groups 1 and 2 (59±21 vs. 500±104 cfu/ml; P < 0.0001). Anti-TNF MAb treatment did not reduce the frequency or level of bacteremia compared to the control group (463± 152 vs. 543± 149 cfu/ml; P = NS).
Serum determinations and monoclonal antibody studies.
Mean anti-TNF MAb levels in pooled sera measured 4 h after intravenous administration of TN3 19.12 was 398±69 ,ug/ml, whereas anti-LPS MAb levels in these same sera were measured at 508±41 ng/ml. Serum TNF levels were undetectable 24 There was no significant difference in the mean TNF levels in animals receiving the irrelevant MAb when compared with the LPS MAb alone (Fig. 2) . Serum TNF levels were significantly higher in group 3 animals which did not survive the duration of the experiment when compared with the six animals in group 3 which survived the duration ofthe experiment (26.0±3.1 vs. 10.3±5.6 U, P < 0.05 by the two-sample t test). Moreover, serum TNF levels were elevated in nonsurviving animals when compared with survivors who received anti-TNF MAb (groups 2 and 4); but these differences did not reach statistical significance (3.7±4.6 vs. 0.6+0.7 U. P = 0.07).
Analysis of the anti-LPS MAb 1.14.1 demonstrated specific binding of P. aeruginosa 12.4.4 LPS only. The Western blot revealed no binding of MAb 1.14.1 to other LPS immunotypes. Limulus reactivity was not altered by the addition of the MAb to P. aeruginosa 12.4.4 LPS, indicating that the MAb lacks significant endotoxin-neutralizing effects (data not shown).
Pathologic findings. Necropsy examination of animals which did not survive the period of neutropenia revealed that 93% had evidence of multisystem infection with the infecting strain of P. aeruginosa 12.4.4. One animal in group 1 died of apparent gastrointestinal hemorrhage and another animal in group 3 had pulmonary hemorrhage. Animals which survived the period of neutropenia (5-7 d) were sacrificed at the end of the experiment (12 d after cyclophosphamide). All bacterial cultures of necropsy material were negative with the exception of cecal cultures which remained positive in 30% of surviving animals. Histologic examination of nonsurviving animals revealed uniform evidence of acute tubular necrosis of renal tissue, mild pulmonary congestion, and interstitial edema in lung tissue and cecal specimens (Fig. 3) . Histologic examination of surviving animals revealed no significant pathologic change in lung, cecal, or renal tissues.
Discussion
There is a sequence of steps through which a potential pathogen that colonizes a mucosal surface must pass before it induces septic shock (Fig. 4) Because each ofthese separate steps involves a different site or target for immunotherapeutic attack, one might expect that the administration of antibodies that function at separate sites, may provide synergistic or at least additive effects, in a manner not unlike the sequential effects of trimethoprim-sulfamethoxazole on the folic acid metabolic pathway of bacteria. This concept was tested in this study. In the absence of antimicrobial therapy, a monoclonal antibody directed at the LPS O-side chain that mediates opsonophagocytosis, or another monoclonal antibody that neutralizes the biological effects of tumor necrosis factor each afforded significant protection from lethal Pseudomonas bacteremia. When given together, however, there was a significantly enhanced survival.
We are currently assessing whether the addition of a third antibody, directed at a core glycolipid determinant that may be important for the biological effects ofLPS, might provide even greater protection against Pseudomonas sepsis. Should this approach result in maximally enhanced protection, then the concept ofa "cocktail" ofmonoclonal antibodies, each designed to overcome activation ofsequential stages ofthe septic process in combination with antimicrobial agents, may become the optimal treatment for septic shock.
Antibodies directed against TNF-a offer a novel immunotherapeutic approach in the management of septic shock. The results of the current study indicate that anti-TNF MAb alone, even in the absence of antimicrobial agents, will partially protect animals from otherwise lethal P. aeruginosa infection during a period ofchemotherapy-induced neutropenia. These findings demonstrate that an anti-TNF MAb not only protects animals in toxicity models (11) (12) (13) (14) but also in an actual infection model (15, 18) . The neutropenic rat model more closely mimics a clinical infection in that endogenously mediated bacteremia occurs after alimentary tract colonization with an opportunistic gram-negative bacillus such as Pseudomonas aeruginosa (17) . The protective efficacy of polyclonal and monoclonal antibody directed against TNF has been amply demonstrated in a variety ofendotoxic models in experimental animals (1 1-14) . The neutropenic rat model offers an opportunity to study the value of this immunotherapeutic approach against a virulent, replicating bacterial infection in an immunocompromised animal (17, 18) .
TNF-a is known to duplicate most of the metabolic and pathophysiologic effects of endotoxin in animal models (11, (22) (23) (24) . Serum TNF levels have been found to be abruptly elevated in endotoxic challenge in human subjects (25) as well as in patients with meningococcemia and infectious purpura (26, 27) . The level of circulating TNF was found to be a prognostic indicator in some human infections, with elevated TNF levels indicating a greater severity of illness (28) and a worse prognosis (26) . Nonsurviving animals receiving an anti-LPS MAb in the current study also demonstrated higher levels of serum TNF compared with surviving animals.
Serotype-specific anti-LPS MAb offers partial protection in this animal model against the infecting strain ofPseudomonas aeruginosa 12.4.4 given intraperitoneally (17), or intravenously, as in the current study. This antibody has been shown to be bacteriocidal in the presence ofphagocytes (20) and promotes clearance of bacteremia even in severely neutropenic animals (17) . Whereas MAb 11.14.1 failed to reduce the frequency of bacteremia in the current study, the antibody did result in a diminished quantitative level ofbacteremia from the infecting strain of P. aeruginosa. The antibody may facilitate the clearance ofP. aeruginosa 12.4.4. by tissue phagocytic cells which continue to function during the neutropenic period.
Despite the partial protection availed by anti-LPS MAb, serum TNF levels were not significantly reduced compared to group 1 control animals. This suggests that the protection afforded by an anti-LPS MAb may not be solely mediated by reduction in serum TNF levels. Similar observations have recently been reported by others (29, 30) . Anti-LPS antibodies would be expected to have a variety of salutary effects despite continued cytokine production. Such antibodies may limit complement activation, endorphin production, or the clotting cascade which would be of benefit to the host during systemic infection (30) . This would also indicate that a combination of anti-LPS and anti-TNF monoclonal antibodies might be expected to have additive or synergistic effects in the prevention oflethal septic shock. The potential utility ofan anti-core glycolipid MAb has yet to be determined in this experimental model of Pseudomonas sepsis. Anti-core glycolipid MAb would be expected to provide broad protection against a variety ofinfecting strains of Pseudomonas aeruginosa as well as gram-negative enteric bacteria. The potential efficacy of anti-core glycolipid MAb has recently been reported in two human trials (31, 32) .
The combination of an anti-LPS and anti-TNF MAb demonstrated additive protective efficacy in this neutropenic rat model of lethal Pseudomonas sepsis. Whether similar results will be obtained using a core glycolipid monoclonal antibody in lieu of a serotype-specific anti-LPS MAb remains to be determined. Certainly this approach of a combination of monoclonal antibodies would provide an attractive therapeutic strategy in the management ofpatients with serious infections with gram-negative bacilli in the presence of neutropenia or other predisposing conditions. The combination of antibodies directed against LPS and TNF-a in addition to standard antimicrobial agents may be the most efficacious therapeutic approach available at the present time. Further studies will be necessary to determine the most appropriate timing and dose of monoclonal antibodies in septic shock state and the potential utility of this approach in the management of a variety of other strains of Pseudomonas aeruginosa as well as enteric gram-negative bacilli.
